Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in Menopausal Women
Published: Aug 28, 2012
BEVERLY HILLS, Calif., Aug. 27, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that it has completed the acquisition of pending patent USPTO #60/719,756, an invention that provides a Method for Relieving Climacteric Symptoms ("Hot Flashes"). According to the 2000 US Census, there are over 37.5 million American women between the ages of 40-59 that are in the age range for pre-menopause, menopause and peri-menopause that have the potential for experiencing hot flash symptoms.
"The Company believes that its Patent Pending Application covering a novel indication of the FDA approved drug homatropine, known as Tropine 3, has substantial strategic value in the rapidly growing women's healthcare market, particularly the menopausal symptom management market," stated Michael Borkowski, CEO and President of Eaton Scientific. "Safe and effective non-hormonal menopausal symptom management is a very high priority issue for many women. Eaton Scientific is well positioned to benefit from this dramatic global market opportunity, as the Company continues to develop market awareness and prepares to introduce Tropine 3 to a much larger audience in the near future."
Eaton Scientific makes the following Claims as part of its USPTO Application #60/719,756 Patent Pending Application, an invention that provides a Method for Relieving Climacteric Symptoms ("Hot Flashes").
The climacteric is defined as the syndrome of endocrine, somatic and psychological changes occurring at the termination of the reproductive period in the female. According to the Greene Climacteric scale (Greene (1998) Maturitas 29:25-31), there are 21 common symptoms associated with a woman's climacteric stage, namely heart beating quickly or strongly, feeling tense or nervous, difficulty in sleeping, excitability, attacks of panic, difficulty in concentrating, feeling tired or lacking in energy, loss of interest in most things, feeling unhappy or depressed, crying spells, irritability, feeling dizzy or faint, pressure or tightness in head or body, parts of the body feel numb or tingling, headaches, muscle and joint pains, loss of feeling in hands and feet, breathing difficulties, hot flushes, sweating at night, and loss of interest in sex. Other symptoms commonly experienced in climacteric women include urinary frequency and urgency, palpitations, and anxiety.
It has now been found that anticholinergic agents, such as homatropine, alleviate hot flushes in peri-menopausal and post-menopausal women. In general, anticholinergic agents work by modulating the activity of muscarinic receptors, which mediate a variety of cellular responses. For example, muscarinic receptors in smooth muscle regulate cardiac contractions, gut motility and bronchial constriction, whereas muscarinic receptors in exocrine glands stimulate gastric acid secretion, salivation and lacrimation. Muscarinic receptors also are found in the superior cervical ganglion, cerebral cortex, the striatum, the hippocampus, thalamus, and brainstem.
Eaton Scientific and its management believe that its USPTO Patent Pending Application is a vital part of its business thesis and as such the company is committed to updating its shareholders to any significant developments in its Application.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.